Bruno Sangro, MD, PhD head of Hepatology Unit, Internal Medicine Department, Clínica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC). 

Usually in phase Ib/II trials, efficacy is not observed. However, in this trial investigating nivolumab, there was clinically relevant anti-tumor activity, explains Sangro.  

According to Sangro, the response rate was between 15% to 20%, the median duration of response was 17 months, and a portion of patients had prolonged stable disease. 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Immuno-Oncology

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the efficacy of nivolumab (Opdivo) in patients with hepatocellular carcinoma (HCC).

Dr. Sangro on the Efficacy of Nivolumab in HCC